2-Methyl-5-(1-propenyl)pyrazine | 108653-51-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Methyl-5-(1-propenyl)pyrazine
• 英文别名: 2-methyl-5-[(E)-prop-1-enyl]pyrazine
• CAS: 108653-51-6；18217-82-8
• 化学式: C₈H₁₀N₂
• 分子量: 134.18
• InChiKey: KFZIJPOISUVMAW-ONEGZZNKSA-N

物化性质

• 沸点：
  200.5±35.0 °C(Predicted)
• 密度：
  1.007±0.06 g/cm3(Predicted)
• 保留指数：
  1146.1

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Flavor extract of low-temperature-pressed peanut cake and method for using the same
  申请人：Institute for Application of Atomic energy, Chinese Academy of Agricultural Sciences

  公开号：US10645963B2

  公开（公告）日：2020-05-12

  The present invention provides a flavor extract of low-temperature-pressed peanut cake which is extracted from low-temperature-pressed peanut cake. In the flavor extract, the content of pyrazines flavor substances is not less than 55%, and the content of the aldehydes substances is not more than 15%. The present invention also provides a method for improving the flavor of peanut oil by using the flavor extract of the low-temperature-pressed peanut cake. The flavor extract extracted from peanut cake according to the present invention, which contains 55% or more pyrazines flavor substances, can not only improve the flavor of low-temperature-pressed peanut oil significantly, but also retain the original quality and color of the low-temperature-pressed peanut oil when it is added to low-temperature-pressed peanut oil.

  本发明提供了一种从低温压榨花生饼中提取的低温压榨花生饼风味提取物。在该风味提取物中，吡嗪类风味物质的含量不低于 55%，醛类物质的含量不高于 15%。本发明还提供了一种利用低温压榨花生饼香精提取物改善花生油风味的方法。根据本发明从花生饼中提取的风味提取物，其中吡嗪类风味物质的含量在55%以上，添加到低温压榨花生油中，不仅可以显著改善低温压榨花生油的风味，还能保持低温压榨花生油原有的品质和色泽。
• Chemosensory receptor ligand-based therapies
  申请人：Anji Pharma (US) LLC

  公开号：US10610500B2

  公开（公告）日：2020-04-07

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

  本文提供了通过施用包含化感受体配体（如苦味受体配体）的组合物来治疗与化感受体相关的病症（包括糖尿病、肥胖症和其他代谢性疾病、失调或病症）的方法。本文还提供了化学感觉受体配体组合物，包括苦味受体配体组合物，及其用于本发明方法的制备方法。本文还提供了包含二甲双胍及其盐类的组合物和使用方法。
• CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES
  申请人：Anji Pharma (US) LLC

  公开号：EP2661266B1

  公开（公告）日：2020-09-16
• HISTONE DEACETYLASE INHIBITORS
  申请人：Bressi C. Jerome

  公开号：US20070149495A1

  公开（公告）日：2007-06-28

  Histone deacetylase inhibitors and uses thereof are provided that have the general formula wherein R 1 , R 2 , R 3 and R 4 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted straight chained C 1-12 alkyl, C 2-12 aminoalkyl or C 2-12 oxaalkyl, and a substituted and unsubstituted 3, 4, 5, 6, 7 or 8 membered ring, with the proviso that R 3 and R 4 are not both hydrogen; R 5 is selected from the group consisting of a carbonyl, a substituted or unsubstituted C 1-3 alkyl, a substituted or unsubstituted —C 1-3 alkyl-C(O), a substituted or unsubstituted —C(O)—C 1-3 alkyl, and a substituted or unsubstituted —C(O)C(O)C 1-3 alkyl; M is a substituent capable of complexing with a protein metal ion; and L is a substituent comprising a chain of 3-12 atoms connecting the M substituent to the carbon atom alpha to the L substituent.
• Chemosensory Receptor Ligand-Based Therapies
  申请人：BARON Alain D.

  公开号：US20120177730A1

  公开（公告）日：2012-07-12

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.